Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

CIIC Stock Is Now Overvalued Before Its Merger With Arrival

By Mark R. Hake, CFA

CIIC stock is worth only $20.66 using present value, or 26% above its own implied value for the merger with Arrival Group.

NextEra Energy Is On a Path to Acquire Another Utility With Its Shares

By Mark R. Hake, CFA

NextEra Energy is on a warpath to acquire another utility using its shares as currency. NEE stock is higher priced than its peers so an acquisition using shares might increase its EPS and lower its P/E.

Here’s Why Boeing Stock Looks Like a Good Turnaround Play

By Mark R. Hake, CFA

Boeing stock looks like a good turnaround play because its average annual gain could be 35% over the next two years for some investors.

Canopy Growth Is Turning Around, Leaving CGC Stock a Huge Upside

By Mark R. Hake, CFA

Canopy Growth seems to be turning around, leaving CGC stock a huge upside. CGC stock is likely to benefit from the company's turnaround and its clearer path toward profitability.

Pfizer Looks Like Good Value With Its Vaccine Catalyst and Dividend Yield

By Mark R. Hake, CFA

Pfizer looks like good value with its vaccine catalyst and dividend yield. PFE stock will be 60% higher within several years after the FDA grants EUA for its Covid-19 vaccine.

Load More